相关临床试验
292
15 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
8
2.7%
已完成
171
58.6%
尚未招募
7
2.4%
招募中
36
12.3%
终止
30
10.3%
Unknown
2
0.7%
撤回
38
13.0%
暂无批准数据
- AN2 Therapeutics announced plans to advance oral epetraborole into a Phase 2 proof-of-concept study for adults with phlebotomy-dependent polycythemia vera, a blood cancer affecting approximately 155,000 people in the U.S. - The decision is supported by clinical evidence showing epetraborole consistently demonstrated early, controlled, sustained, and dose-dependent hematocrit reductions across multiple clinical populations including healthy volunteers and NTM lung disease patients. - The Phase 2 trial is expected to begin in the third quarter of 2026 in India, with potential data readouts as early as fourth quarter 2026 and throughout 2027. - Epetraborole operates through a potentially differentiated mechanism targeting globin synthesis rather than heme synthesis, offering red-cell selectivity while sparing white blood cells and platelets.
- The pivotal Bridge to HOPE clinical trial demonstrates that Hypothermic Oxygenated Perfusion (HOPE) reduces liver transplant costs by an average of $28,565 per patient compared to standard cold storage. - HOPE significantly decreased severe organ rejection rates (32% vs 67%) and steroid-resistant rejection (4% vs 43%) while shortening hospital stays by over 2 days. - The VitaSmart Perfusion System used with HOPE showed reduced complications including fewer biliary issues, re-transplants, and deaths in 12-month follow-up data. - Multiple presentations at the 2025 World Transplant Congress highlighted HOPE's clinical, economic, and immunomodulatory advantages for liver transplantation.
